
  
    
      
        Introduction_NNP
        MI_NNP is_VBZ a_DT potentially_RB catastrophic_JJ event_NN in_IN patients_NNS
        presenting_VBG with_IN acute_JJ coronary_JJ syndromes_NNS ._. In_IN recent_JJ trials_NNS
        of_IN antiplatelet_NN and_CC antithrombotic_JJ therapies_NNS for_IN such_JJ
        patients_NNS ,_, prevention_NN of_IN MI_NNP was_VBD the_DT primary_JJ treatment_NN effect_NN
        assessed_VBD [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 4_CD ]_NN ._. Although_IN MI_NNP has_VBZ been_VBN considered_VBN a_NNP
        '_POS hard_JJ '_POS end-point_JJ ,_, determination_NN of_IN MI_NNP end-points_JJ in_IN
        clinical_JJ trials_NNS can_MD be_VB difficult_JJ ,_, just_RB as_IN in_IN clinical_JJ
        practice_NN ._. Because_IN of_IN conflicting_JJ clinical_JJ ,_, laboratory_NN ,_, and_CC
        electrocardiography_NN (_( ECG_NNP )_) data_NNS ,_, physicians_NNS often_RB disagree_VBP
        whether_IN a_DT patient_NN has_VBZ suffered_VBN a_DT MI_NNP ._. The_DT importance_NN of_IN
        low-level_JJ enzyme_NN elevations_NNS also_RB has_VBZ been_VBN controversial_JJ ,_,
        particularly_RB in_IN asymptomatic_JJ patients_NNS and_CC in_IN those_DT
        undergoing_VBG percutaneous_JJ coronary_JJ intervention_NN (_( PCI_NNP )_) [_NN 5_CD ]_NN ._.
        Although_IN such_JJ enzyme_NN elevations_NNS are_VBP defined_VBN as_IN MIs_NNP in_IN many_JJ
        trial_NN protocols_NNS ,_, physicians_NNS in_IN clinical_JJ practice_NN do_VBP not_RB
        consistently_RB consider_VB them_PRP as_IN such_JJ ._. The_DT MI_NNP rates_NNS reported_VBN
        by_IN site_NN investigators_NNS in_IN recent_JJ cardiovascular_JJ trials_NNS have_VBP
        differed_VBD from_IN rates_NNS adjudicated_JJ by_IN a_DT CEC_NNP [_NN 6_CD ,_, 7_CD ,_, 8_CD ,_, 9_CD ]_NN ._. The_DT
        reasons_NNS for_IN these_DT differences_NNS are_VBP unclear_JJ ._.
        CECs_NNP are_VBP widely_RB accepted_VBN to_TO adjudicate_NN suspected_VBD
        endpoint_NN events_NNS in_IN trials_NNS ,_, but_CC only_RB limited_JJ information_NN has_VBZ
        been_VBN published_VBN regarding_VBG end-point_JJ adjudication_NN [_NN 10_CD ,_, 11_CD ,_,
        12_CD ,_, 13_CD ,_, 14_CD ,_, 15_CD ]_NN ._. In_IN the_DT PURSUIT_NNP trial_NN [_NN 6_CD ]_NN ,_, a_DT central_JJ ,_,
        independent_JJ CEC_NNP systematically_RB identified_VBD and_CC adjudicated_JJ
        all_DT suspected_VBN MIs_NNP that_WDT occurred_VBD up_IN to_TO 30_CD days_NNS after_IN
        enrolment_NN ._. The_DT rationale_NN for_IN CEC_NNP adjudication_NN was_VBD the_DT need_NN
        for_IN a_DT systematic_JJ ,_, unbiased_JJ ,_, independent_JJ ,_, and_CC standard_JJ
        assessment_NN of_IN MIs_NNP in_IN a_DT large_JJ international_JJ trial_NN ._. In_IN a_DT
        previous_JJ analysis_NN of_IN the_DT CEC_NNP process_NN in_IN the_DT PURSUIT_NNP trial_NN ,_,
        we_PRP found_VBD that_IN the_DT CEC_NNP and_CC site_NN investigator_NN assessments_NNS of_IN
        end-point_JJ MI_NNP disagreed_VBD in_IN ~_NN 10_CD %_NN of_IN patients_NNS [_NN 16_CD ]_NN ._. We_PRP
        retrospectively_RB reviewed_VBD these_DT cases_NNS ,_, to_TO identify_VB reasons_NNS
        for_IN them_PRP and_CC to_TO understand_VB their_PRP$ potential_JJ effect_NN on_IN the_DT
        trial_NN results_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          The_DT PURSUIT_NNP trial_NN
          The_DT PURSUIT_NNP trial_NN examined_VBD the_DT role_NN of_IN eptifibatide_NN ,_, a_DT
          platelet_NN glycoprotein_NN IIb_NNP /_NN IIIa_NNP antagonist_NN ,_, in_IN patients_NNS
          presenting_VBG with_IN acute_JJ coronary_JJ syndromes_NNS without_IN
          persistent_JJ ST-segment_NNP elevation_NN ._. The_DT trial_NN enrolled_VBD
          10_CD ,_, 948_CD patients_NNS in_IN 726_CD hospitals_NNS in_IN 27_CD countries_NNS in_IN North_NNP
          America_NNP ,_, Latin_NNP America_NNP ,_, Western_NNP Europe_NNP ,_, and_CC Eastern_NNP
          Europe_NNP ,_, using_VBG previously_RB reported_VBD inclusion_NN and_CC exclusion_NN
          criteria_NNS and_CC treatment_NN regimens_NNS [_NN 6_CD ]_NN ._. The_DT primary_JJ
          end-point_JJ was_VBD a_DT composite_NN of_IN death_NN or_CC post-enrolment_JJ MI_NNP
          (_( or_CC reinfarction_NN if_IN patients_NNS had_VBD a_DT MI_NNP at_IN enrolment_NN )_) by_IN 30_CD
          days_NNS as_IN adjudicated_JJ by_IN a_DT CEC_NNP ._. The_DT composite_JJ end-point_JJ was_VBD
          also_RB constructed_VBN using_VBG the_DT site_NN investigator_NN
          determination_NN of_IN MI_NNP ._.
        
        
          Definitions_NNP
          The_DT protocol_NN defined_VBD MI_NNP as_IN an_DT end-point_JJ event_NN based_VBN on_IN
          clinical_JJ ,_, ECG_NNP ,_, and_CC laboratory_NN criteria_NNS (_( see_VB Appendix_NNP )_) ;_:
          MIs_NNP that_WDT occurred_VBD before_IN or_CC at_IN enrolment_NN were_VBD not_RB
          included_VBN in_IN the_DT primary_JJ end-point_JJ ._. The_DT site_NN investigators_NNS
          and_CC the_DT CEC_NNP used_VBD the_DT same_JJ MI_NNP criteria_NNS ._. These_DT criteria_NNS
          were_VBD presented_VBN in_IN the_DT protocol_NN ,_, at_IN investigator_NN meetings_NNS ,_,
          and_CC in_IN trial_NN materials_NNS and_CC newsletters_NNS ._.
        
        
          Data_NNP collection_NN
          Data_NNP were_VBD captured_VBN on_IN standard_JJ case_NN report_NN forms_NNS ._.
          Information_NNP collected_VBD for_IN all_DT patients_NNS included_VBD cardiac_JJ
          enzymes_NNS ,_, ECGs_NNP (_( at_IN the_DT time_NN of_IN the_DT qualifying_VBG episode_NN ,_, at_IN
          enrolment_NN ,_, at_IN 24_CD hours_NNS ,_, at_IN initial_JJ discharge_NN ,_, and_CC at_IN 30_CD
          days_NNS )_) ,_, revascu-larisation_JJ procedure_NN reports_NNS ,_, details_NNS of_IN
          ischemic_JJ episodes_NNS ,_, clinical_JJ complications_NNS ,_, medications_NNS ,_,
          and_CC readmission_NN records_NNS ._. All_DT enzyme_NN values_NNS for_IN each_DT
          patient_NN were_VBD to_TO be_VB reported_VBN ,_, and_CC study_NN monitors_VBZ verified_VBN
          them_PRP against_IN source_NN documents_NNS ._. For_IN patients_NNS with_IN
          suspected_VBN MI_NNP ,_, site_NN investigators_NNS were_VBD to_TO submit_VB
          supporting_VBG documents_NNS and_CC to_TO include_VB discharge_NN summaries_NNS
          and_CC additional_JJ ECGs_NNP during_IN the_DT suspected_VBN event_NN ._. An_DT
          independent_JJ ,_, blinded_JJ ,_, ECG_NNP Core_NNP Laboratory_NNP read_VBD the_DT ECGs_NNP
          and_CC identified_VBN suspected_VBN MIs_NNP ,_, defined_VBN as_IN new_JJ Q_NNP waves_NNS â‰¥_NN
          0_CD ._. 04_CD s_VBZ in_IN two_CD contiguous_JJ leads_NNS ._.
        
        
          Clinical_NNP events_NNS classification_NN process_NN
          The_DT structure_NN of_IN the_DT CEC_NNP and_CC the_DT event_NN adjudication_NN
          process_NN have_VBP been_VBN reported_VBN in_IN detail_NN elsewhere_RB [_NN 16_CD ]_NN ._.
          Computer_NN algorithms_NNS systematically_RB identified_VBN key_JJ
          clinical_JJ ,_, enzymatic_JJ ,_, and_CC ECG_NNP data_NNS from_IN the_DT database_NN that_WDT
          could_MD indicate_VB the_DT occurrence_NN of_IN a_DT MI_NNP ._. Each_DT case_NN of_IN
          suspected_VBN MI_NNP was_VBD reviewed_VBN independently_RB by_IN two_CD physicians_NNS
          blinded_JJ to_TO treatment_NN ._. If_IN the_DT physicians_NNS agreed_VBD that_IN a_DT MI_NNP
          had_VBD or_CC had_VBN not_RB occurred_VBN ,_, the_DT case_NN was_VBD classified_VBN as_IN
          resolved_VBN ._. A_DT committee_NN of_IN faculty_NN cardiologists_NNS reviewed_VBD
          patients_NNS about_IN which_WDT the_DT CEC_NNP physicians_NNS disagreed_VBD ,_, for_IN
          adjudication_NN by_IN consensus_NN ._.
        
        
          Disagreements_NNP between_IN the_DT site_NN investigators_NNS and_CC
          CEC_NNP
          A_DT faculty_NN cardiologist_NN (_( KWM_NNP ,_, RAH_NNP ,_, BSC_NNP )_) re-reviewed_JJ
          patients_NNS with_IN disagreement_NN between_IN the_DT site_NN investigator_NN
          assessment_NN and_CC the_DT CEC_NNP adjudication_NN of_IN end-point_JJ MI_NNP ,_, to_TO
          determine_VB reasons_NNS for_IN the_DT disagreement_NN ._. This_DT review_NN
          occurred_VBD after_IN the_DT main_JJ trial_NN results_NNS were_VBD presented_VBN ,_, but_CC
          the_DT reviewers_NNS were_VBD blinded_JJ to_TO patient_NN treatment_NN
          assignment_NN ._. Patients_NNS were_VBD categorised_JJ during_IN the_DT
          re-review_JJ in_IN clinically_RB meaningful_JJ groups_NNS :_: MI_NNP at_IN
          enrolment_NN (_( versus_CC post-enrolment_JJ MI_NNP )_) ,_, MI_NNP related_VBD to_TO the_DT
          revascularisation_NN procedure_NN ,_, MI_NNP related_VBD to_TO clinically_RB
          evident_JJ ischemia_NN ,_, asymptomatic_JJ cardiac_JJ enzyme_NN elevation_NN
          post-enrolment_JJ ,_, and_CC clinically_RB significant_JJ cardiac_JJ event_NN
          resulting_VBG in_IN death_NN (_( versus_CC sudden_JJ death_NN without_IN evidence_NN
          of_IN MI_NNP )_) ._.
          Despite_IN rigorous_JJ criteria_NNS to_TO define_VB MI_NNP ,_, some_DT patients_NNS
          required_VBD a_DT subjective_JJ assessment_NN by_IN CEC_NNP physicians_NNS if_IN
          cardiac_JJ enzyme_NN ,_, ECG_NNP ,_, and_CC clinical_JJ information_NN conflicted_VBN ._.
          For_IN patients_NNS with_IN MI_NNP identified_VBN by_IN the_DT CEC_NNP but_CC not_RB by_IN the_DT
          site_NN investigator_NN (_( excluding_VBG events_NNS after_IN PCI_NNP or_CC bypass_VB
          surgery_NN )_) ,_, we_PRP therefore_RB assigned_VBN a_DT level_NN of_IN clinical_JJ
          certainty_NN ._. A_DT high_JJ clinical_JJ certainty_NN was_VBD assigned_VBN when_WRB
          all_DT clinicians_NNS agreed_VBD that_IN a_DT MI_NNP had_VBD occurred_VBN ;_: a_DT low_JJ
          clinical_JJ certainty_NN was_VBD assigned_VBN when_WRB only_RB some_DT clinicians_NNS
          would_MD agree_VB that_IN a_DT MI_NNP had_VBD occurred_VBN ._.
        
        
          Statistical_NNP analysis_NN
          Data_NNP regarding_VBG the_DT number_NN of_IN patients_NNS with_IN suspected_VBN
          events_NNS and_CC those_DT with_IN disagreements_NNS between_IN the_DT site_NN
          investigators_NNS and_CC the_DT CEC_NNP were_VBD obtained_VBN from_IN the_DT entire_JJ
          PURSUIT_NNP study_NN population_NN ,_, so_IN the_DT data_NNS included_VBD patients_NNS
          assigned_VBN high-dose_JJ eptifibatide_NN ,_, low-dose_JJ eptifibatide_NN ,_,
          or_CC placebo_NN ._. Comparisons_NNP by_IN treatment_NN assignments_NNS included_VBD
          only_RB patients_NNS assigned_VBN to_TO high-dose_JJ eptifibatide_NN or_CC
          placebo_NN to_TO maintain_VB consistency_NN with_IN the_DT primary_JJ efficacy_NN
          analysis_NN in_IN the_DT PURSUIT_NNP trial_NN [_NN 6_CD ]_NN ._. 
          P_NN values_NNS were_VBD calculated_VBN using_VBG the_DT
          Î§_NN 2_CD test_NN ._.
        
      
      
        Results_NNS
        
          Incidence_NNP of_IN disagreement_NN
          Overall_RB ,_, 5005_CD (_( 46_CD %_NN )_) patients_NNS with_IN possible_JJ or_CC
          suspected_VBN MI_NNP were_VBD identified_VBN and_CC adjudicated_JJ by_IN the_DT CEC_NNP ._.
          The_DT CEC_NNP identified_VBD more_JJR patients_NNS with_IN end-point_JJ events_NNS
          than_IN did_VBD the_DT site_NN investigators_NNS (_( 13_CD ._. 6_CD %_NN versus_CC 7_CD ._. 7_CD %_NN for_IN
          placebo_NN ,_, 12_CD ._. 6_CD %_NN versus_CC 6_CD ._. 2_CD %_NN for_IN eptifibatide_NN )_) ._. The_DT CEC_NNP and_CC
          site_NN investigator_NN assessments_NNS of_IN MI_NNP disagreed_VBD for_IN 9_CD %_NN of_IN
          all_DT patients_NNS enrolled_VBD in_IN the_DT PURSUIT_NNP trial_NN ._. The_DT CEC_NNP
          identified_VBD MIs_NNP in_IN 1415_CD of_IN the_DT 5005_CD patients_NNS with_IN
          suspected_VBN MI_NNP ._. The_DT site_NN investigator_NN and_CC the_DT CEC_NNP
          assessments_NNS disagreed_VBD in_IN 983_CD (_( 20_CD %_NN )_) of_IN the_DT 5005_CD patients_NNS ._.
          Of_IN these_DT 983_CD patients_NNS with_IN disagreements_NNS ,_, 816_CD patients_NNS
          had_VBD a_DT MI_NNP identified_VBN by_IN the_DT CEC_NNP but_CC not_RB the_DT site_NN
          investigator_NN ,_, and_CC 167_CD patients_NNS had_VBD a_DT MI_NNP identified_VBN by_IN
          site_NN investigator_NN but_CC not_RB the_DT CEC_NNP ._. The_DT proportion_NN of_IN
          patients_NNS with_IN disagreement_NN was_VBD similar_JJ among_IN regions_NNS ._.
        
        
          Reasons_NNS for_IN disagreement_NN
          Most_JJS often_RB ,_, when_WRB the_DT site_NN investigator_NN had_VBD identified_VBN
          a_DT MI_NNP and_CC the_DT CEC_NNP had_VBD not_RB ,_, the_DT investigator_NN had_VBD
          misclassified_VBN a_DT MI_NNP at_IN enrolment_NN as_IN an_DT end-point_JJ MI_NNP ,_,
          although_IN by_IN protocol_NN these_DT were_VBD not_RB end-point_JJ events_NNS
          (_( Table_NNP 1_LS )_) ._. Recurrent_NNP ischemic_JJ events_NNS without_IN elevated_VBD
          cardiac_JJ enzymes_NNS or_CC ECG_NNP evidence_NN of_IN MI_NNP were_VBD also_RB
          incorrectly_RB identified_VBN by_IN site_NN investigators_NNS as_IN MIs_NNP
          (_( Table_NNP 1_LS )_) ._. In_IN cases_NNS where_WRB the_DT CEC_NNP had_VBD identified_VBN a_DT MI_NNP and_CC
          the_DT site_NN investigators_NNS had_VBD not_RB ,_, one-third_NN of_IN those_DT
          identified_VBN were_VBD MIs_NNP defined_VBN by_IN enzyme_NN elevations_NNS without_IN
          clinical_JJ or_CC ECG_NNP evidence_NN of_IN ischemia_NN or_CC infarction_NN (_( Table_NNP
          2_LS )_) ._. Enzyme_NNP elevations_NNS after_IN bypass_NN surgery_NN accounted_VBD for_IN
          25_CD %_NN of_IN these_DT cases_NNS ._. Patients_NNS with_IN clinically_RB evident_JJ
          ischemia_NN reported_VBN by_IN the_DT site_NN investigator_NN and_CC associated_VBN
          with_IN cardiac_JJ enzyme_NN elevations_NNS were_VBD not_RB reported_VBN as_IN MIs_NNP
          by_IN investigators_NNS in_IN 27_CD %_NN of_IN the_DT cases_NNS of_IN disagreement_NN
          (_( Table_NNP 2_LS )_) ._. Few_JJ infarctions_NNS based_VBN on_IN new_JJ Q_NNP waves_NNS without_IN
          clinical_JJ evidence_NN of_IN reinfarction_NN were_VBD identified_VBN by_IN the_DT
          CEC_NNP and_CC not_RB by_IN site_NN investigators_NNS ._.
          Table_NNP 3_CD presents_VBZ the_DT cardiac_JJ enzyme_NN elevation_NN for_IN MIs_NNP
          that_IN the_DT CEC_NNP identified_VBD and_CC the_DT site_NN investigators_NNS did_VBD
          not_RB ._. These_DT data_NNS exclude_VBP MIs_NNP associated_VBN with_IN PCI_NNP or_CC bypass_VB
          surgery_NN ;_: by_IN definition_NN ,_, those_DT types_NNS of_IN MI_NNP required_VBD enzyme_NN
          elevations_NNS greater_JJR than_IN three_CD or_CC five_CD times_NNS the_DT upper_JJ
          limit_NN of_IN normal_JJ (_( ULN_NNP )_) ,_, respectively_RB ._. The_DT ratio_NN of_IN
          creatine_NN kinase-myocardial_JJ band_NN (_( CK-MB_NNP )_) to_TO its_PRP$ ULN_NNP was_VBD
          highest_JJS in_IN North_NNP America_NNP (_( median_JJ [_NN 25_CD th_NN ,_, 75_CD th_NN ]_NN 1_CD ._. 6_CD [_NN 1_CD ._. 2_LS ,_,
          2_CD ._. 9_CD ]_NN )_) ._. Enzymes_NNP were_VBD similarly_RB elevated_VBD between_IN patients_NNS
          with_IN MIs_NNP defined_VBD only_RB by_IN enzyme_NN elevations_NNS (_( without_IN
          symptoms_NNS or_CC ECG_NNP changes_NNS )_) and_CC patients_NNS with_IN elevations_NNS
          associated_VBN with_IN ECG_NNP or_CC clinical_JJ evidence_NN of_IN ischemia_NN ._.
          Table_NNP 4_CD presents_VBZ the_DT level_NN of_IN clinical_JJ certainty_NN for_IN
          MIs_NNP not_RB associated_VBN with_IN PCI_NNP or_CC bypass_VB surgery_NN ,_, as_IN
          identified_VBN by_IN the_DT CEC_NNP but_CC not_RB the_DT site_NN investigators_NNS ._.
          Overall_RB ,_, 98_CD (_( 18_CD %_NN )_) of_IN these_DT patients_NNS were_VBD assigned_VBN a_DT low_JJ
          level_NN of_IN clinical_JJ certainty_NN ._. The_DT proportion_NN of_IN patients_NNS
          assigned_VBN a_DT low_JJ level_NN of_IN clinical_JJ certainty_NN varied_VBD among_IN
          the_DT regions_NNS ,_, with_IN the_DT lowest_JJS in_IN North_NNP America_NNP ._.
        
        
          Effect_NN of_IN disagreement_NN on_IN outcomes_NNS
          The_DT 30_CD -_: day_NN CEC_NNP rates_NNS of_IN MI_NNP and_CC death_NN or_CC MI_NNP overall_JJ are_VBP
          presented_VBN in_IN Table_NNP 5_CD by_IN geographic_JJ region_NN ._. The_DT event_NN rates_NNS
          are_VBP also_RB shown_VBN for_IN the_DT analyses_NNS in_IN which_WDT the_DT 98_CD patients_NNS
          assigned_VBN a_DT low_JJ level_NN of_IN certainty_NN were_VBD reclassified_VBD as_IN no_DT
          infarction_NN ._.
          The_DT lowest_JJS mortality_NN rates_NNS were_VBD in_IN patients_NNS for_IN whom_WP
          the_DT CEC_NNP and_CC site_NN investigators_NNS agreed_VBD that_IN no_DT MI_NNP had_VBD
          occurred_VBN by_IN 30_CD days_NNS (_( Table_NNP 6_CD )_) ._. The_DT highest_JJS rates_NNS were_VBD in_IN
          patients_NNS for_IN whom_WP there_EX was_VBD agreement_NN that_IN a_DT MI_NNP had_VBD
          occurred_VBN ._. Mortality_NNP was_VBD high_JJ in_IN the_DT group_NN with_IN MI_NNP
          identified_VBN by_IN the_DT site_NN investigators_NNS but_CC not_RB the_DT CEC_NNP ;_:
          however_RB ,_, many_JJ of_IN these_DT patients_NNS had_VBD suspected_VBN sudden_JJ
          cardiac_JJ death_NN as_IN the_DT event_NN identified_VBN as_IN a_DT MI_NNP by_IN the_DT
          investigator_NN (_( Table_NNP 1_LS )_) ._. The_DT absolute_JJ increase_NN in_IN
          mortality_NN between_IN 30_CD days_NNS and_CC 6_CD months_NNS was_VBD greater_JJR in_IN
          patients_NNS with_IN CEC-determined_NNP MIs_NNP not_RB identified_VBN by_IN the_DT
          site_NN investigators_NNS than_IN in_IN patients_NNS with_IN MI_NNP identified_VBN by_IN
          the_DT site_NN investigators_NNS but_CC not_RB the_DT CEC_NNP ._.
        
      
      
        Discussion_NNP
        
          Event_NN rates_NNS
          The_DT MI_NNP rates_NNS adjudicated_JJ by_IN the_DT CEC_NNP in_IN the_DT PURSUIT_NNP
          trial_NN were_VBD higher_JJR than_IN those_DT reported_VBN in_IN trials_NNS of_IN
          similar_JJ patient_NN populations_NNS [_NN 6_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ]_NN ._. The_DT reasons_NNS
          for_IN these_DT higher_JJR rates_NNS have_VBP been_VBN detailed_JJ previously_RB [_NN
          16_CD ]_NN ,_, and_CC include_VBP the_DT review_NN of_IN nearly_RB 50_CD %_NN of_IN patients_NNS by_IN
          physicians_NNS to_TO identify_VB suspected_VBN events_NNS ,_, more_RBR liberal_JJ MI_NNP
          criteria_NNS ,_, and_CC rigorous_JJ measurement_NN of_IN cardiac_JJ enzymes_NNS in_IN
          all_DT patients_NNS ._. Studies_NNS that_WDT have_VBP used_VBN only_RB
          investigator-reported_JJ events_NNS probably_RB underestimate_NN the_DT
          true_JJ MI_NNP rate_NN ._.
        
        
          Lack_NN of_IN concordance_NN between_IN site_NN investigator_NN and_CC
          CEC_NNP event_NN rates_NNS
          Site_NNP investigators_NNS underreported_JJ MIs_NNP ._. A_DT similar_JJ lack_NN
          of_IN concordance_NN between_IN events_NNS adjudicated_JJ by_IN a_DT CEC_NNP and_CC
          those_DT identified_VBN by_IN clinical_JJ investigators_NNS has_VBZ been_VBN
          observed_VBN in_IN trials_NNS in_IN which_WDT a_DT similar_JJ CEC_NNP group_NN
          adjudicated_JJ MIs_NNP [_NN 1_CD ,_, 8_CD ]_NN and_CC in_IN other_JJ trials_NNS [_NN 7_CD ,_, 9_CD ]_NN ._.
          The_DT MI_NNP definitions_NNS in_IN the_DT PURSUIT_NNP trial_NN were_VBD
          formulated_VBN by_IN the_DT International_NNP Steering_NNP Committee_NNP based_VBN
          on_IN experience_NN and_CC clinical_JJ expertise_NN ._. Because_IN of_IN the_DT
          broad_JJ geographic_JJ enrolment_NN planned_VBN for_IN the_DT PURSUIT_NNP trial_NN ,_,
          definitions_NNS were_VBD designed_VBN to_TO be_VB applicable_JJ in_IN an_DT array_NN of_IN
          clinical_JJ practice_NN situations_NNS ._. The_DT definitions_NNS were_VBD
          detailed_JJ in_IN the_DT study_NN protocol_NN ,_, in_IN study_NN newsletters_NNS ,_, and_CC
          in_IN study_NN materials_NNS so_IN the_DT CEC_NNP and_CC site_NN investigators_NNS had_VBD
          the_DT same_JJ set_NN of_IN criteria_NNS to_TO classify_VB MIs_NNP ._.
          The_DT reasons_NNS for_IN disagreements_NNS in_IN MI_NNP assessment_NN between_IN
          the_DT site_NN investigators_NNS and_CC the_DT CEC_NNP in_IN the_DT PURSUIT_NNP trial_NN
          (_( Tables_NNP 1_CD and_CC 2_LS )_) are_VBP similar_JJ to_TO those_DT seen_VBN in_IN the_DT Global_NNP
          Use_NN of_IN Strategies_NNS to_TO Open_NNP Occluded_NNP Arteries_NN in_IN Acute_NNP
          Coronary_NNP Syndromes_NNP (_( GUSTO-IIb_NNP )_) and_CC the_DT Integrilin_NNP to_TO
          Minimize_NNP Platelet_NNP Aggregation_NNP and_CC Coronary_NNP Thrombosis_NNP
          (_( IMPACT-II_NNP )_) trials_NNS (_( unpublished_JJ personal_JJ data_NNS )_) ._. Many_JJ of_IN
          the_DT disagreements_NNS reflect_VBP physician_NN reluctance_NN to_TO
          diagnose_NN MI_NNP in_IN patients_NNS they_PRP are_VBP treating_VBG ,_, particularly_RB
          when_WRB the_DT definition_NN of_IN MI_NNP includes_VBZ events_NNS with_IN low-level_JJ
          cardiac_JJ enzyme_NN elevations_NNS (_( often_RB called_VBN '_POS enzyme_NN leaks_NNS '_POS in_IN
          clinical_JJ practice_NN )_) ._. This_DT reluctance_NN by_IN physicians_NNS to_TO
          diagnose_NN MI_NNP is_VBZ also_RB apparent_JJ for_IN patients_NNS undergoing_VBG PCI_NNP ,_,
          in_IN which_WDT the_DT clinical_JJ significance_NN of_IN postprocedural_NN
          enzyme_NN elevations_NNS is_VBZ controversial_JJ ,_, even_RB though_IN such_JJ
          elevations_NNS correlate_VBP with_IN worse_JJR outcome_NN [_NN 5_CD ]_NN ._.
          The_DT disagreements_NNS also_RB may_MD partly_RB reflect_VB the_DT
          definitions_NNS (_( see_VB Appendix_NNP )_) of_IN MI_NNP themselves_PRP ._. These_DT
          definitions_NNS were_VBD designed_VBN to_TO be_VB applied_VBN to_TO a_DT broad_JJ set_NN of_IN
          clinical_JJ scenarios_NNS ,_, including_VBG events_NNS after_IN PCI_NNP or_CC bypass_VB
          surgery_NN ,_, and_CC to_TO events_NNS occurring_VBG early_RB after_IN enrolment_NN ,_,
          which_WDT needed_VBD to_TO be_VB differentiated_JJ from_IN pre-enrolment_JJ or_CC
          enrolment_NN MIs_NNP ._. Site_NNP investigators_NNS may_MD have_VB had_VBN difficulty_NN
          applying_VBG these_DT criteria_NNS ,_, particularly_RB with_IN conflicting_JJ
          cardiac_JJ enzyme_NN ,_, ECG_NNP ,_, and_CC clinical_JJ information_NN ._. In_IN
          addition_NN ,_, the_DT enzyme_NN criteria_NNS in_IN the_DT PURSUIT_NNP trial_NN
          required_VBN only_RB one_CD cardiac_JJ enzyme_NN value_NN above_IN normal_JJ to_TO
          provide_VB supportive_JJ evidence_NN of_IN MI_NNP ._. Substantial_NNP clinical_JJ
          uncertainty_NN exists_VBZ regarding_VBG the_DT need_NN for_IN more_JJR than_IN one_CD
          elevated_VBD enzyme_NN value_NN and_CC whether_IN the_DT CK-MB_NNP criteria_NNS
          should_MD specify_VB elevations_NNS greater_JJR than_IN 1_CD Ã—_NN ULN_NNP or_CC 2_CD Ã—_NN
          ULN_NNP ._.
          The_DT strategy_NN used_VBN by_IN a_DT CEC_NNP to_TO adjudicate_NN MIs_NNP can_MD
          dramatically_RB influence_VB event_NN rates_NNS and_CC the_DT proportion_NN of_IN
          events_NNS with_IN disagreements_NNS between_IN site_NN investigators_NNS and_CC
          a_DT CEC_NNP ._. Some_DT trials_NNS have_VBP confirmed_VBN only_RB events_NNS reported_VBN by_IN
          the_DT investigators_NNS [_NN 9_CD ,_, 17_CD ,_, 18_CD ,_, 19_CD ,_, 20_CD ,_, 21_CD ]_NN ,_, while_IN other_JJ
          trials_NNS have_VBP adjudicated_JJ all_DT suspected_VBN events_NNS identified_VBN
          by_IN systematic_JJ screening_NN of_IN patient_NN data_NNS [_NN 1_CD ,_, 2_CD ,_, 3_CD ,_, 7_CD ,_, 8_CD ,_,
          22_CD ]_NN ._. When_WRB only_RB events_NNS reported_VBN by_IN investigators_NNS are_VBP
          reviewed_VBN by_IN a_DT CEC_NNP ,_, the_DT reported_VBN event_NN rates_NNS will_MD be_VB
          identical_JJ to_TO or_CC lower_JJR than_IN the_DT site_NN investigator_NN rates_NNS ._.
          When_WRB events_NNS are_VBP identified_VBN independently_RB by_IN the_DT CEC_NNP ,_, the_DT
          CEC_NNP event_NN rates_NNS may_MD be_VB higher_JJR ,_, lower_RBR ,_, or_CC the_DT same_JJ as_IN the_DT
          site_NN investigator-reported_JJ rates_NNS ._.
        
        
          Difference_NNP in_IN treatment_NN effect_NN
          The_DT absolute_JJ difference_NN in_IN the_DT MI_NNP rates_NNS was_VBD 1_CD ._. 6_CD %_NN (_( 6_CD ._. 2_LS %_NN
          for_IN eptifibatide_NN versus_CC 7_CD ._. 8_CD %_NN for_IN placebo_NN )_) as_IN assessed_VBN by_IN
          the_DT site_NN investigators_NNS ,_, and_CC 1_CD ._. 0_CD %_NN (_( 12_CD ._. 6_CD %_NN versus_CC 13_CD ._. 6_CD %_NN )_) as_IN
          adjudicated_JJ by_IN the_DT CEC_NNP ._. The_DT higher_JJR event_NN rates_NNS in_IN both_DT
          treatment_NN arms_NNS using_VBG the_DT CEC_NNP data_NN ,_, despite_IN the_DT similar_JJ
          absolute_JJ difference_NN ,_, reduced_VBD the_DT relative_JJ treatment_NN
          effect_NN (_( 7_CD ._. 4_LS %_NN versus_CC 20_CD ._. 5_LS %_NN reduction_NN )_) as_IN expected_VBN ._. A_DT
          similar_JJ decrease_NN in_IN relative_JJ treatment_NN effect_NN has_VBZ been_VBN
          noted_VBN in_IN some_DT trials_NNS [_NN 1_CD ,_, 8_CD ]_NN but_CC not_RB others_NNS [_NN 17_CD ,_, 18_CD ,_,
          19_CD ]_NN ._.
          The_DT MIs_NNP determined_VBN by_IN cardiac_JJ enzyme_NN elevations_NNS
          without_IN clinical_JJ symptoms_NNS or_CC ECG_NNP changes_NNS accounted_VBD for_IN
          33_CD %_NN of_IN the_DT disagreements_NNS in_IN which_WDT the_DT CEC_NNP identified_VBD a_DT MI_NNP
          and_CC the_DT site_NN investigators_NNS did_VBD not_RB ._. The_DT median_JJ CK-MB_NNP
          elevation_NN in_IN these_DT events_NNS was_VBD 1_CD ._. 6_CD Ã—_NN ULN_NNP ._. About_IN 50_CD %_NN of_IN
          these_DT events_NNS were_VBD thus_RB defined_VBN by_IN CK-MB_NNP values_NNS between_IN 1_CD
          Ã—_NN ULN_NNP and_CC 1_CD ._. 5_CD Ã—_NN ULN_NNP ,_, with_IN normal_JJ median_JJ CK_NNP values_NNS (_( 0_CD ._. 9_CD Ã—_NN
          ULN_NNP )_) (_( Table_NNP 3_LS )_) ._.
          A_DT retrospective_NN but_CC blinded_JJ review_NN of_IN MIs_NNP identified_VBN
          by_IN the_DT CEC_NNP but_CC not_RB the_DT site_NN investigator_NN found_VBD that_IN 18_CD %_NN
          (_( 98_CD /_NN 540_CD )_) of_IN these_DT patients_NNS were_VBD assigned_VBN a_DT low_JJ level_NN of_IN
          clinical_JJ certainty_NN ._. This_DT was_VBD because_IN ,_, although_IN the_DT CK_NNP or_CC
          CK-MB_NNP elevations_NNS met_VBD the_DT end-point_JJ criteria_NNS ,_, the_DT cardiac_JJ
          enzyme_NN data_NNS were_VBD considered_VBN inconsistent_JJ or_CC unreliable_JJ ,_,
          or_CC were_VBD associated_VBN with_IN conflicting_JJ clinical_JJ and_CC ECG_NNP
          data_NNS ._.
          We_PRP noted_VBD regional_JJ differences_NNS in_IN the_DT proportion_NN of_IN
          patients_NNS with_IN low_JJ clinical_JJ certainty_NN ._. The_DT highest_JJS
          proportions_NNS were_VBD in_IN Eastern_NNP Europe_NNP and_CC Latin_NNP America_NNP ,_,
          where_WRB the_DT observed_VBN treatment_NN effect_NN using_VBG the_DT CEC_NNP
          definition_NN was_VBD negligible_JJ ._. Furthermore_RB ,_, the_DT magnitude_NN of_IN
          the_DT enzyme_NN elevations_NNS (_( Table_NNP 3_LS )_) parallels_NNS discrepancies_NNS
          in_IN the_DT assigned_VBN level_NN of_IN certainty_NN ._. The_DT highest_JJS enzyme_NN
          elevations_NNS were_VBD observed_VBN in_IN North_NNP America_NNP (_( median_JJ CK-MB_NNP
          elevation_NN ,_, 2_CD ._. 9_CD Ã—_NN ULN_NNP ;_: median_JJ CK_NNP elevation_NN ,_, 1_CD ._. 6_CD Ã—_NN ULN_NNP )_) ,_,
          where_WRB the_DT treatment_NN effect_NN was_VBD mostpronounced_JJ ._. CK-MB_NNP
          elevations_NNS in_IN other_JJ regions_NNS were_VBD less_RBR striking_JJ (_( median_JJ
          CK-MB_NNP elevation_NN ,_, 1_CD ._. 4_CD Ã—_NN ULN-_NNP 2_CD ._. 0_CD Ã—_NN ULN_NNP )_) ._. The_DT regional_JJ
          differences_NNS in_IN treatment_NN effect_NN are_VBP ,_, however_RB ,_, complex_JJ and_CC
          include_VBP differences_NNS in_IN patient_NN demographics_NNS ,_, the_DT use_NN of_IN
          cardiac_JJ procedures_NNS ,_, medications_NNS and_CC revascularisation_NN ,_,
          and_CC the_DT reliability_NN of_IN laboratory_NN data_NNS [_NN 23_CD ]_NN ._. These_DT
          findings_NNS support_VBP the_DT hypothesis_NNS that_IN including_VBG MI_NNP
          end-points_JJ defined_VBD by_IN low-level_JJ cardiac_JJ enzyme_NN elevations_NNS
          or_CC events_NNS associated_VBN with_IN conflicting_JJ clinical_JJ and_CC ECG_NNP
          data_NNS may_MD dilute_VB the_DT actual_JJ treatment_NN effect_NN ._.
        
        
          Predictive_NNP value_NN of_IN CEC-identified_NNP events_NNS
          The_DT 30_CD -_: day_NN treatment_NN effect_NN was_VBD reduced_VBN using_VBG
          CEC-adjudicated_NNP end-points_JJ versus_CC site_NN investigator_NN
          assessments_NNS ,_, but_CC patients_NNS with_IN events_NNS adjudicated_JJ by_IN the_DT
          CEC_NNP (_( but_CC not_RB identified_VBN by_IN the_DT site_NN investigators_NNS )_) had_VBD
          greater_JJR mortality_NN between_IN 30_CD days_NNS and_CC 6_CD months_NNS than_IN did_VBD
          patients_NNS with_IN MI_NNP reported_VBD only_RB by_IN the_DT site_NN investigators_NNS
          (_( Table_NNP 6_CD )_) ._. In_IN addition_NN ,_, MIs_NNP identified_VBN by_IN a_DT similar_JJ CEC_NNP
          process_NN have_VBP been_VBN associated_VBN with_IN worse_RBR long-term_JJ
          outcomes_NNS at_IN 3_CD -_: year_NN follow-up_JJ [_NN 24_CD ]_NN ._. These_DT data_NNS suggest_VBP
          that_IN events_NNS identified_VBN by_IN the_DT CEC_NNP alone_RB are_VBP of_IN prognostic_JJ
          importance_NN ._.
        
      
      
        Implications_NNP
        CEC_NNP adjudication_NN of_IN suspected_VBN nonfatal_NN MI_NNP end-point_JJ
        events_NNS is_VBZ important_JJ to_TO provide_VB independent_JJ ,_, unbiased_JJ ,_,
        standard_JJ ,_, systematic_JJ assessment_NN ._. The_DT CEC_NNP adjudication_NN does_VBZ
        have_VB certain_JJ limitations_NNS ._. The_DT criteria_NNS used_VBN to_TO define_VB MI_NNP
        must_MD be_VB evaluated_VBN ._. The_DT determination_NN of_IN MI_NNP may_MD require_VB more_RBR
        clinical_JJ judgment_NN in_IN patients_NNS with_IN inconsistent_JJ clinical_JJ
        history_NN ,_, cardiac_JJ enzyme_NN data_NNS ,_, and_CC ECG_NNP information_NN ,_, or_CC
        suspect_VBP cardiac_JJ enzyme_NN data_NNS ._. We_PRP recognise_NN that_IN this_DT may_MD
        decrease_VB the_DT objectivity_NN that_WDT is_VBZ important_JJ for_IN event_NN
        classification_NN ,_, particularly_RB in_IN trials_NNS across_IN geographic_JJ
        regions_NNS and_CC clinical_JJ practice_NN settings_NNS ._. At_IN a_DT minimum_NN ,_,
        events_NNS characterised_JJ by_IN a_DT low_JJ level_NN of_IN clinical_JJ certainty_NN
        should_MD not_RB be_VB classified_VBN as_IN MIs_NNP ._.
        Although_IN the_DT absolute_JJ difference_NN in_IN infarction_NN rates_NNS
        determined_VBN by_IN the_DT CEC_NNP versus_CC site_NN investigators_NNS was_VBD small_JJ ,_,
        the_DT relative_JJ difference_NN was_VBD more_RBR substantial_JJ ._. This_DT caused_VBD a_DT
        substantial_JJ impact_NN on_IN the_DT statistical_JJ outcome_NN of_IN the_DT trial_NN ._.
        This_DT phenomenon_NN must_MD be_VB considered_VBN in_IN calculations_NNS of_IN
        sample_NN size_NN and_CC power_NN during_IN design_NN of_IN future_JJ trials_NNS ,_, and_CC
        also_RB may_MD influence_VB how_WRB clinical_JJ and_CC regulatory_JJ bodies_NNS
        interpret_VBP trial_NN results_NNS ._. In_IN addition_NN ,_, the_DT CEC_NNP process_NN used_VBN
        must_MD be_VB considered_VBN ,_, among_IN other_JJ factors_NNS ,_, when_WRB performing_VBG
        comparisons_NNS of_IN event_NN rates_NNS between_IN trials_NNS ._.
      
      
        Conclusions_NNP
        Nonfatal_NNP MI_NNP is_VBZ an_DT important_JJ clinical_JJ outcome_NN ,_, and_CC its_PRP$
        prevention_NN is_VBZ a_DT key_JJ measure_NN of_IN efficacy_NN in_IN evaluating_VBG new_JJ
        therapies_NNS for_IN acute_JJ coronary_JJ syndromes_NNS ._. The_DT determination_NN
        of_IN MI_NNP can_MD be_VB difficult_JJ in_IN clinical_JJ practice_NN due_JJ to_TO
        conflicting_JJ clinical_JJ ,_, cardiac_JJ enzyme_NN ,_, and_CC ECG_NNP data_NNS ._. The_DT CEC_NNP
        adjudication_NN of_IN MI_NNP provides_VBZ a_DT standard_JJ ,_, systematic_JJ ,_,
        independent_JJ ,_, and_CC unbiased_JJ assessment_NN of_IN this_DT end-point_JJ in_IN
        clinical_JJ investigations_NNS ._. In_IN the_DT PURSUIT_NNP trial_NN ,_, the_DT
        assessments_NNS of_IN MI_NNP by_IN site_NN investigators_NNS and_CC a_DT central_JJ CEC_NNP
        disagreed_VBD ;_: more_JJR MIs_NNP were_VBD identified_VBN by_IN the_DT CEC_NNP than_IN by_IN site_NN
        investigators_NNS ._. Most_JJS disagreements_NNS reflected_VBD underreporting_VBG
        of_IN procedure-related_JJ events_NNS and_CC misclassification_NN of_IN
        enrolment_NN MIs_NNP as_IN post-enrolment_JJ (_( end-point_JJ )_) MIs_NNP ._.
        Understanding_NNP the_DT CEC_NNP process_NN used_VBN in_IN a_DT trial_NN is_VBZ important_JJ
        in_IN interpreting_VBG event_NN rates_NNS ,_, particularly_RB when_WRB comparing_VBG
        rates_NNS between_IN trials_NNS ._. The_DT type_NN of_IN CEC_NNP process_NN also_RB has_VBZ
        implications_NNS in_IN calculations_NNS of_IN sample_NN size_NN and_CC power_NN ._. Our_PRP$
        review_NN of_IN the_DT PURSUIT_NNP trial_NN CEC_NNP experience_NN has_VBZ highlighted_VBN
        some_DT of_IN these_DT important_JJ issues_NNS and_CC the_DT need_NN to_TO further_VB
        evaluate_VB the_DT strategies_NNS used_VBN for_IN event_NN adjudication_NN ._.
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Abbreviations_NNP
        CEC_NNP =_SYM clinical_JJ events_NNS committee_NN ;_: CK-MB_NNP =_SYM creatine_NN
        kinase-myocardial_JJ band_NN ;_: ECG_NNP =_SYM electrocardiography_NN ;_: MI_NNP =_SYM
        myocardial_NN infarction_NN ;_: PCI_NNP =_SYM percutaneous_JJ coronary_JJ
        intervention_NN ;_: PURSUIT_NNP =_SYM Platelet_NNP Glycoprotein_NNP IIb_NNP /_NN IIIa_NNP in_IN
        Unstable_NNP Angina_NNP :_: Receptor_NNP Suppression_NN Using_VBG Integrilin_NNP
        (_( Eptifibatide_NNP )_) Therapy_NNP ;_: ULN_NNP =_SYM upper_JJ limit_NN of_IN normal_JJ ._.
      
      
        Appendix_NNP :_: definition_NN for_IN post-enrolment_JJ myocardial_NN
        infarction_NN
        
          Enzyme_NNP criteria_NNS
          1_LS ._. Myocardial_NNP infarction_NN (_( events_NNS without_IN documentation_NN
          of_IN previous_JJ infarction_NN during_IN the_DT admission_NN )_) :_: creatine_NN
          kinase-myocardial_JJ band_NN (_( CK-MB_NNP )_) level_NN above_IN the_DT upper_JJ
          limit_NN of_IN normal_JJ (_( ULN_NNP )_) and_CC â‰¥_NN 3_CD %_NN of_IN total_JJ CK_NNP ._. If_IN CK-MB_NNP was_VBD
          unavailable_JJ ,_, then_RB total_JJ CK_NNP >_NN 2_CD Ã—_NN ULN_NNP ._.
          2_LS ._. Myocardial_NNP reinfarction_NN (_( events_NNS with_IN documentation_NN
          of_IN an_DT infarction_NN before_IN or_CC at_IN enrolment_NN )_) :_:
          If_IN <_NN 18_CD hours_NNS since_IN previous_JJ infarction_NN ._. Recurrent_NNP ,_,
          severe_JJ ischemic_JJ discomfort_NN and_CC new_JJ ,_, recurrent_JJ ST-segment_NNP
          elevation_NN â‰¥_NN 0_CD ._. 1_CD mV_NN in_IN at_IN least_JJS two_CD contiguous_JJ leads_NNS ,_,
          either_CC persisting_VBG â‰¥_NN 30_CD min_NN ._.
          If_IN â‰¥_NN 18_CD hours_NNS since_IN previous_JJ infarction_NN ._. Re-elevation_NNP
          of_IN CK-MB_NNP to_TO above_IN the_DT ULN_NNP (_( if_IN prior_JJ CK-MB_NNP was_VBD within_IN
          normal_JJ range_NN )_) or_CC >_NN 50_CD %_NN above_IN the_DT prior_JJ level_NN (_( if_IN prior_JJ
          CK-MB_NNP was_VBD above_IN normal_JJ )_) ._. If_IN CK-MB_NNP was_VBD unavailable_JJ :_: either_CC
          total_JJ CK_NNP â‰¥_NN 2_CD Ã—_NN ULN_NNP and_CC increased_VBN by_IN â‰¥_NN 25_CD %_NN ;_: or_CC â‰¥_NN 1_CD ._. 5_CD Ã—_NN ULN_NNP
          and_CC increased_VBN by_IN â‰¥_NN 200_CD IU_NNP above_IN prior_JJ value_NN ._.
          3_LS ._. Periprocedural_NNP infarction_NN (_( events_NNS occurring_VBG during_IN
          or_CC within_IN 24_CD hours_NNS of_IN percutaneous_JJ coronary_JJ
          intervention_NN )_) :_: CK-MB_NNP level_NN â‰¥_NN 3_CD Ã—_NN ULN_NNP and_CC >_NN 50_CD %_NN above_IN
          prior_JJ nadir_NN value_NN ._. If_IN CK-MB_NNP was_VBD unavailable_JJ ,_, total_JJ CK_NNP â‰¥_NN 3_CD
          Ã—_NN ULN_NNP ._.
          4_LS ._. Perioperative_NNP infarction_NN (_( events_NNS occurring_VBG during_IN
          or_CC within_IN 36_CD hours_NNS of_IN bypass_NN surgery_NN )_) :_: CK-MB_NNP â‰¥_NN 5_CD Ã—_NN ULN_NNP
          (_( or_CC CK_NNP ,_, in_IN the_DT absence_NN of_IN CK-MB_NNP )_) ._.
        
        
          ECG_NNP criteria_NNS
          New_NNP ,_, significant_JJ Q_NNP waves_NNS or_CC equivalents_NNS â‰¥_NN 0_CD ._. 04_CD s_VBZ in_IN at_IN
          least_JJS two_CD contiguous_JJ leads_NNS ._. When_WRB enzyme_NN or_CC
          electrocardiographic_JJ (_( ECG_NNP )_) data_NNS were_VBD unavailable_JJ ,_, an_DT
          infarction_NN was_VBD identified_VBN when_WRB the_DT bulk_NN of_IN clinical_JJ
          evidence_NN (_( patient_NN signs_NNS ,_, symptoms_NNS ,_, ECG_NNP changes_NNS ,_, and_CC
          pathological_JJ findings_NNS )_) so_RB indicated_VBD ._.
        
      
    
  
